Non-Cochrane · intervention · PM42220288
Effectiveness of extracorporeal shock wave therapy for temporomandibular disorders: a systematic review and meta-analysis.
Liu Shunyuan, Shuai Yuli, Ye Liu, et al. · Journal of oral & facial pain and headache · 2026 · PubMed · doi:10.22514/jofph.2026.036
Findings
Population Adults with temporomandibular disorders
4 findings
| Extracorporeal shock wave therapy (ESWT) alone | Ultrashort wave therapy and/or ultrasound therapy | Pain (VAS) Post-treatment (treatment duration 2 to 4 weeks) · Overall | MD -0.81 [-1.77, 0.16] Very low Downgraded: risk of bias, inconsistency 2 studies · 160 participants |
| Extracorporeal shock wave therapy (ESWT) alone | Ultrashort wave therapy and/or ultrasound therapy | Maximum mouth opening (MMO) Post-treatment (treatment duration 2 to 4 weeks) · Overall | SMD -1.84 [-18.43, 14.74] Very low Downgraded: risk of bias, inconsistency 2 studies · 160 participants |
| ESWT combined with other treatments | The same other treatments without ESWT | Pain (VAS) Post-treatment (treatment duration 2 to 4 weeks) · Overall | MD 0.94 [0.61, 1.26] Low Downgraded: risk of bias 12 studies · 947 participants |
| ESWT combined with other treatments | The same other treatments without ESWT | Maximum mouth opening (MMO) Post-treatment (treatment duration 2 to 4 weeks) · Overall | SMD 0.69 [0.48, 0.90] Very low Downgraded: risk of bias, inconsistency 10 studies · 829 participants |
Included primary studies 11
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Wang 2020 matched by author and year (probable) | NR | 5 other reviews | not stated | not extracted yet |
| Wang 2024 matched by author and year (probable) | NR | 3 other reviews | not stated | not extracted yet |
| Chen 2022 matched by author and year (probable) | NR | 1 other review | not stated | not extracted yet |
| Keskin Tunc 2024 Can extracorporeal shock wave therapy be effective in temporomandibular joint disorder?: A pilot study. PMID:39470554 | 2024 | 1 other review | not stated | not extracted yet |
| Keskin Tunç 2024 Can extracorporeal shock wave therapy be effective in temporomandibular joint disorder?: A pilot study DOI:10.1097/md.0000000000040052 | 2024 | 1 other review | not stated | not extracted yet |
| Li 2020 Treatment of Temporomandibular Joint Disorders by Ultrashort Wave and Extracorporeal Shock Wave: A Comparative Study DOI:10.12659/msm.923461 | 2020 | 1 other review | not stated | not extracted yet |
| Li 2020 Treatment of Temporomandibular Joint Disorders by Ultrashort Wave and Extracorporeal Shock Wave: A Comparative Study. PMID:32564051 | 2020 | 1 other review | not stated | not extracted yet |
| Song 2024 matched by author and year (probable) | NR | 1 other review | not stated | not extracted yet |
| Hu 2023b Myotonic dystrophy type 1 and PGD: ovarian stimulation response and correlation analysis between ovarian reserve and genotype. PMID:20231114 | 2010 | this review only | not stated | not extracted yet |
| Wang P 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Wang PC 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Adults (18 years or older) with temporomandibular disorders confirmed by DC/TMD, RDC/TMD or clear clinical description | Adults with temporomandibular disorders (n=1107 in 14 RCTs) |
| Intervention | Any study group receiving ESWT | ESWT alone (2 RCTs); ESWT combined with other treatments (12 RCTs) |
| Comparison | Not specified | Ultrashort wave and/or ultrasound therapy (ESWT alone); other treatments without ESWT (adjunct analyses) |
| Outcomes | Visual analog scale (VAS) for pain or maximum mouth opening (MMO); at least one required | Pain VAS (k=2 alone; k=12 adjunct); MMO (k=2 alone; k=10 adjunct) |
| Study designs | Randomized controlled trials | Randomized controlled trials (n=14) |
| Timing | Not specified | Treatment duration 2 to 4 weeks; no long-term follow-up |
AMSTAR 2 items
Two independent extractors rated each item. Their ratings are shown side by side because they have not been reconciled yet. The overall rating follows Shea et al. 2017: one critical flaw gives Low, more than one gives Critically Low.
| Item | Extractor A | Extractor B | Agree |
|---|---|---|---|
| 1Research question includes PICO components | No | No | yes |
| 2Protocol established before the reviewcritical | Partial Yes | Partial Yes | yes |
| 3Choice of study designs explained | No | No | yes |
| 4Comprehensive literature searchcritical | Partial Yes | Partial Yes | yes |
| 5Study selection in duplicate | Yes | Yes | yes |
| 6Data extraction in duplicate | Yes | Yes | yes |
| 7List of excluded studies with reasonscritical | No | No | yes |
| 8Included studies described in detail | Partial Yes | Partial Yes | yes |
| 9Risk of bias assessed satisfactorilycritical | RCT: Yes · NRSI: N/A | NRSI: N/A · RCT: Yes | no |
| 10Funding of included studies reported | No | No | yes |
| 11Appropriate meta-analysis methodscritical | RCT: Yes · NRSI: N/A | NRSI: N/A · RCT: Yes | no |
| 12Impact of risk of bias on the pooled results | No | No | yes |
| 13Risk of bias accounted for in interpretationcritical | Yes | Yes | yes |
| 14Heterogeneity explained | Yes | Yes | yes |
| 15Publication bias investigatedcritical | Yes | Yes | yes |
| 16Conflicts of interest reported | Yes | Yes | yes |
| Overall | Low | Low | yes |